Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina Pectoris

• Status: Not yet recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a randomized, double-blind, placebo-controlled, parallel clinical trial in Chinese population with stable angina pectoris. The purpose is to determine the efficacy and safety of Xueshuanxinmaining tablet in the treatment of stable angina pectoris.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
• Treatments: Nitroglycerin

Criteria

Inclusion Criteria:

• Participants are aged between 40 and 75 years.

• Meet the diagnostic criteria of stable angina pectoris.

• Meet Chinese medicine syndrome differentiation of Qi-yin deficiency and blood stasis syndrome.

• Voluntarily participate and sign informed consent.

Exclusion Criteria:

• Patients were diagnosed as acute myocardial infarction, unstable angina, stable exertion angina and other heart diseases.

• Patients with poor control of hypertension and diabetes, severe cardiopulmonary insufficiency, severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, etc.), with a history of heart pacemaker or cerebrovascular disease within one year.

• Any of the following disease history or evidence was found in the screening period:

severe cardiovascular or cerebrovascular diseases; active, recurrent peptic ulcer or other bleeding risk diseases; other serious diseases of digestive system; combined with malignant tumor, blood system disease, serious or progressive diseases of the other system; combined with mental diseases.

• Before screening, any laboratory inspection index meets the following standards: The results showed that Glutamic aspartate transaminase (AST) or alanine aminotransferase (ALT) were more than 1.5 times of the upper limit of normal value and serum creatinine (Cr) was more than 1.2 times of the upper limit of normal value.

• With a history of alcohol and drug abuse.

• Pregnant or lactating women.

• Patients who have participated in clinical trials of other drugs within 3 months before enrollment.